[Results of open post-registration clinical trials of copaxone in patients with multiple sclerosis]

What Was Tested

The paper reports a study of Glatiramer Acetate in the context of multiple sclerosis, published as a clinical trial.

Results of the 2-year open postregistration study of Copaxone (glatiramer acetate), conducted in 3 Moscow leading medical centres are given. 32 MS patients with remitting-relapsing MS were investigated in accordance with international requirements (neurological scales, MRI of the brain, multimodal evoked potential).

Who Took Part

According to the abstract, 32 patients were involved.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized.

Because people in this Glatiramer Acetate study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

Topics PubMed links to this paper include Adjuvants, Immunologic, Disability Evaluation, Glatiramer Acetate, Multiple Sclerosis, Relapsing-Remitting, Peptides and Randomized Controlled Trials as Topic.

What This Means in Plain Language

The paper is a randomized study of Glatiramer Acetate in 32 patients in people with multiple sclerosis.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2002 (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova), a journal based in Russia (Federation).

More context: the Glatiramer Acetate compound page, Multiple sclerosis research.